DATE: 14 Dec 2021 CATEGORY: PRESS RELEASE Ichnos Sciences and Almirall Enter Into a Licensing Agreement for First-In-Class IL-1RAP Antagonist Monoclonal Antibody Almirall is Granted Exclusive Global Rights to Develop…
DATE: 18 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Preclinical Data Package on First-in-class Oncology Treatment, ISB 1442, at IO360 Conference [FOR IMMEDIATE RELEASE]NEW YORK, NYMARCH 18, 2022NEW YORK,…
DATE: 23 Mar 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Presentation Of Additional Preclinical Data on ISB 1442 For Relapsed/Refractory Multiple Myeloma at AACR 2022 Annual Meeting ISB 1442 is…
DATE: 09 May 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Selection of Trispecific Antibody ISB 2001 as Next Clinical Candidate for Relapsed/Refractory Multiple Myeloma First TREAT™ Trispecific Antibody Targeting BCMA and…
DATE: 03 Nov 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Data Selected for Presentation at the 64th ASH Annual Meeting Four presentations on three oncology assets, including an oral session on…
DATE: 12 Dec 2022 CATEGORY: PRESS RELEASE Ichnos Sciences Presents Data Supporting Three Oncology Assets at ASH 2022 Annual Meeting Ichnos presentations include clinical and preclinical data on ISB 1342…
DATE: 07 July 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Trispecific Antibody, ISB 2001 The US Food and Drug Administration grants orphan drug designation to…
DATE: 20 Mar 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Receives Orphan Drug Designation for First-In-Class Bispecific (CD38 x CD47) Antibody Innate Cell Modulator, ISB 1442 The US Food and Drug…
DATE: 11 Oct 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Enters Licensing Agreement For OX40 Antagonist Monoclonal Antibody Portfolio With Astria Therapeutics Astria Therapeutics is granted global rights to develop and…
DATE: 02 Nov 2023 CATEGORY: PRESS RELEASE Ichnos Sciences Announces Initiation of First-In-Human Clinical Trial for ISB 2001 First patient dosed with company’s TREAT™ trispecific antibody targeting relapsed or refractory…
